United States District Court for the District of Delaware

Concurrently, Eiser executed a scheme from December 2020 to September 2024, which fraudulently accessed Meta Platforms Incorporated business manager accounts and lines of credit to generate over $37 million in illicit sales to advertising companies while evading $13.2 million in federal taxes by concealing corporate ownership and transferring funds to cryptocurrency custodians.

Now, staying with the US, Deborah Evans Mott of Florida has been convicted of making false statements under penalty of perjury in a bankruptcy proceeding following a four-day trial in the District of Delaware.

Federal prosecutors established that as the controlling and majority member of Team Systems International LLC, Mott intentionally concealed closed corporate bank accounts and omitted more than $3 million in transfers to herself and family members from Team Systems' statement of financial affairs after the firm filed Chapter 11 bankruptcy in January 2022 following a $6 million civil judgment.

Mott was convicted on one count of making false statements under penalty of perjury and acquitted on a second count concerning deposition testimony.

In 2020, the FDA approved Hikma's application with the skinny label and assigned an AB rating indicating therapeutic equivalence to Vesepa when used according to its labeling.

Ameren filed suit in the District of Delaware alleging that HICMA actively induced others to infringe Ameren's CV indication patents based on the totality of HICMA's statements across the skinny label, the patient information leaflet, HICMA's website, and its press releases.

The district court granted HICMA's motion to dismiss for failure to state a claim, explaining that none of these statements constituted active steps to encourage infringement.

The Federal Circuit reversed, finding it at least plausible that a physician could read the relevant statements as an instruction or encouragement to infringe.

To ensure that its labeling otherwise mirrored VASIPA's C21USC Section 355J2A5, requiring generic labeling to be the same as the brand name labeling with a few exceptions, Hikmah also removed the CV limitation of use from its proposed label.

In 2020, the FDA approved Hikma's ANDA with the skinny label and assigned Hikma's generic drug an AB rating, indicating that it is therapeutically equivalent to Vesepa when used according to its labeling.

Soon after Hikma began marketing its generic drug, Ameren filed suit in the District of Delaware, alleging that Hikma had actively induced others to infringe Ameren's patent for the CV indication method of use.

Ameren alleged that the totality of Hikma's statements across several documents encouraged infringing uses.

[on-hold music] And finally, the signals underneath the headlines.

In the courts, Corteva and Inari settled the suit Corteva filed in twenty twenty-three in the US District Court for the District of Delaware.

Inari will destroy the Corteva seed material and assign the related intellectual property to Corteva.

In Brazil, Switch Bioworks received approval from CTNBio to field test its engineered nitrogen-fixing microbes in soybean and corn.

Let me point this out.

Ladies and gentlemen, the US District Court, Delaware District Court, uh, found that the ban on making possessing ghost guns unconstitutional.

You're sitting in jail right now in New York for what other courts are finding to be unconstitutional.

That is likely, when it's all said and done, going to be found to be unconstitutional in the long run, but that's not helping you right now.

The third case went the other way.

It's Thomson Reuters versus Ross Intelligence out of the East Coast, out of the District of Delaware.

And here...

The company Ross Intelligence took the Westlaw headnotes that we all know all too well as practicing lawyers, and they took Westlaw headnotes without authorization from Thomson Reuters to train their own competing legal research tool.